Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. (Q38851434)
Jump to navigation
Jump to search
scientific article published on 25 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. |
scientific article published on 25 January 2017 |
Statements
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials (English)
R M Savic
M Weiner
W R MacKenzie
M Engle
W C Whitworth
J L Johnson
P Nsubuga
N V Nguyen
C A Peloquin
K E Dooley
S E Dorman
Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention
1 reference